As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > ORGANIZATION
ORGANIZATION
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
- Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
- Introduce Permanent Price Maintenance Scheme, Don’t Rush on CEA Debate: UA Zensen
September 7, 2017
- JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
- LINK-J Expanding Free Consultation Service for Academic Researchers
August 31, 2017
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
- Impact of Drug Price Revisions on Company Management Unclear: JMA Think Tank
August 22, 2017
- JPWA Member Firms Suffer Record 3.5% Sales Fall on Drop-Off in Demand for Hepatitis C Meds
August 16, 2017
- Science Council of Japan Calls for Public-Private Partnerships to Spur Development of Psychiatric Disease Treatments
August 9, 2017
- New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
- EFPIA Japan to Provide 1 Million Yen to Support Patients’ Organizations
July 5, 2017
- Generic Use Rate at 65.5% in FY2016: JGA
June 30, 2017
- JMA Announces Endorsement for Chuikyo Rep Replacements
June 26, 2017
- FPMAJ Weighs Refined Version of “Similar Treatment Comparison” Pricing Method
June 20, 2017
- FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
June 20, 2017
- Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
June 20, 2017
- FPMAJ Calls for “Cautious” Discussions on Reduction of Price Band for Generic Drugs
June 19, 2017
- FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…